Drug Profile
Infliximab biosimilar - Genor Biopharma
Alternative Names: GB 242; JiayujianLatest Information Update: 23 Oct 2022
Price :
$50
*
At a glance
- Originator Genor Biopharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 31 Aug 2022 Launched for Rheumatoid arthritis (Treatment-experienced) in China (IV). prior to September 2022
- 23 Feb 2022 Preregistration for Rheumatoid arthritis (Treatment-experienced) in China (IV), before March 2022
- 23 Feb 2022 Registered for Rheumatoid arthritis (Treatment-experienced) in China (IV)